Armenia vs Australia: Statin use vs. average non-HDL cholesterol levels
Armenia
3.2
in 2018
Australia
3.2
in 2018
Armenia rank
118th
Australia rank
118th
Statin use vs. average non-HDL cholesterol levels over time
- Armenia
- Australia
How they compare
Armenia currently reports 3.2 against 3.2 in Australia, a difference of 0.
Across all 39 years both countries report, Australia has been ahead every year.
Armenia ranks 118th and Australia ranks 118th of 191 countries.
Australia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Armenia | Australia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.49 | 4.2 | 0.71 | Australia |
| 1990s | 3.36 | 4.06 | 0.7 | Australia |
| 2000s | 3.23 | 3.7 | 0.47 | Australia |
| 2010s | 3.2 | 3.36 | 0.1556 | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Armenia or Australia?
- Armenia, at 3.2 against 3.2 in Australia as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Armenia and Australia?
- 0, with Armenia ahead.
- How many years of comparable data are there for Armenia and Australia?
- 39 years are reported by both, from 1980 to 2018.
- How do Armenia and Australia rank globally for statin use vs. average non-hdl cholesterol levels?
- Armenia ranks 118th and Australia ranks 118th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.